KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Leases (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Operating Leases for 6 consecutive years, with $6.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 3.78% year-over-year to $6.2 million, compared with a TTM value of $6.2 million through Sep 2025, up 3.78%, and an annual FY2024 reading of $5.7 million, down 12.05% over the prior year.
  • Operating Leases was $6.2 million for Q3 2025 at Aurinia Pharmaceuticals, up from $5.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.2 million in Q3 2022 and bottomed at $5.3 million in Q2 2025.
  • Average Operating Leases over 5 years is $6.8 million, with a median of $6.9 million recorded in 2023.
  • The sharpest move saw Operating Leases grew 5.04% in 2022, then dropped 25.44% in 2025.
  • Year by year, Operating Leases stood at $7.7 million in 2021, then decreased by 6.88% to $7.2 million in 2022, then decreased by 8.7% to $6.5 million in 2023, then decreased by 12.05% to $5.7 million in 2024, then rose by 7.54% to $6.2 million in 2025.
  • Business Quant data shows Operating Leases for AUPH at $6.2 million in Q3 2025, $5.3 million in Q2 2025, and $6.6 million in Q1 2025.